BIOVERATIV INC. Financial Statements (2026 and earlier)
Company Profile
| Business Address |
225 2ND AVENUE WALTHAM, MA 02451 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in millions)
| 12/31/2017 | |||
|---|---|---|---|
| ASSETS | |||
| Current Assets | |||
| Cash, cash equivalents, and short-term investments | |||
| Cash and cash equivalent | |||
| Receivables | |||
| Inventory, net of allowances, customer advances and progress billings | |||
| Inventory | |||
| Other current assets | |||
| Other undisclosed current assets | |||
| Total current assets: | |||
| Noncurrent Assets | |||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | |||
| Intangible asset, including goodwill, after accumulated amortization | |||
| Goodwill | |||
| Intangible asset, excluding goodwill, after accumulated amortization | |||
| Other noncurrent assets | |||
| Deferred tax assets, net | |||
| Total noncurrent assets: | |||
| TOTAL ASSETS: | |||
| LIABILITIES AND EQUITY | |||
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities | |||
| Taxes payable | |||
| Employee-related liabilities | |||
| Accounts payable | |||
| Accrued liabilities | |||
| Business combination, contingent consideration, liability | |||
| Due to related parties | |||
| Other undisclosed current liabilities | |||
| Total current liabilities: | |||
| Noncurrent Liabilities | |||
| Liabilities, other than long-term debt | |||
| Deferred tax liabilities, net | |||
| Other liabilities | |||
| Business combination, contingent consideration, liability | |||
| Total noncurrent liabilities: | |||
| Total liabilities: | |||
| Equity | |||
| Equity, attributable to parent | |||
| Common stock | |||
| Additional paid in capital | |||
| Retained earnings | |||
| Total equity: | |||
| TOTAL LIABILITIES AND EQUITY: | |||
Income Statement (P&L) ($ in millions)
| 12/31/2017 | ||
|---|---|---|
| Revenues (Revenue, Net) | ||
| Cost of revenue (Cost of Product and Service Sold) | ||
| Other undisclosed gross profit | ||
| Gross profit: | ||
| Operating expenses | ||
| Operating income: | ||
| Nonoperating income | ||
| Income from continuing operations before income taxes: | ||
| Income tax expense | ||
| Income from continuing operations: | ||
| Income before gain (loss) on sale of properties: | ||
| Net income available to common stockholders, diluted: | ||
Comprehensive Income ($ in millions)
| 12/31/2017 | ||
|---|---|---|
| Net income: | ||
| Other comprehensive loss | ||
| Comprehensive income, net of tax, attributable to parent: | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.